These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 21282541)

  • 1. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y;
    Int J Hematol; 2024 Jun; 119(6):647-659. PubMed ID: 38532078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
    Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
    Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
    Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
    Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
    Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
    Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
    Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Cooper TM; Absalon MJ; Alonzo TA; Gerbing RB; Leger KJ; Hirsch BA; Pollard J; Razzouk BI; Aplenc R; Kolb EA
    J Clin Oncol; 2020 Jul; 38(19):2170-2177. PubMed ID: 32401633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
    Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
    Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
    J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.
    Feldman EJ; Kolitz JE; Trang JM; Liboiron BD; Swenson CE; Chiarella MT; Mayer LD; Louie AC; Lancet JE
    Leuk Res; 2012 Oct; 36(10):1283-9. PubMed ID: 22840315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.
    Issa GC; Kantarjian HM; Xiao L; Ning J; Alvarado Y; Borthakur G; Daver N; DiNardo CD; Jabbour E; Bose P; Jain N; Kadia TM; Naqvi K; Pemmaraju N; Takahashi K; Verstovsek S; Andreeff M; Kornblau SM; Estrov Z; Ferrajoli A; Garcia-Manero G; Ohanian M; Wierda WG; Ravandi F; Cortes JE
    Leukemia; 2020 Nov; 34(11):2914-2924. PubMed ID: 32546726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
    Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
    Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.